Caricamento...
Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases
Infliximab was the first monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). Over several years, this antitumour necrosis factor (TNF) treatment proved its efficacy in both induction and maintenance therapy. In many cases this biological treatment stopped the progression o...
Salvato in:
| Pubblicato in: | Therap Adv Gastroenterol |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4984328/ https://ncbi.nlm.nih.gov/pubmed/27582886 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16650155 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|